| First Author | Wang P | Year | 2013 |
| Journal | Mol Cell Biol | Volume | 33 |
| Issue | 18 | Pages | 3689-99 |
| PubMed ID | 23878390 | Mgi Jnum | J:204741 |
| Mgi Id | MGI:5543307 | Doi | 10.1128/MCB.00343-13 |
| Citation | Wang P, et al. (2013) MicroRNA 329 suppresses angiogenesis by targeting CD146. Mol Cell Biol 33(18):3689-99 |
| abstractText | CD146, an endothelial biomarker, has been shown to be aberrantly upregulated during pathological angiogenesis and functions as a coreceptor for vascular endothelial growth factor receptor 2 (VEGFR-2) to promote disease progression. However, the regulatory mechanisms of CD146 expression during angiogenesis remain unclear. Using a microRNA screening approach, we identified a novel negative regulator of angiogenesis, microRNA 329 (miR-329), that directly targeted CD146 and inhibited CD146-mediated angiogenesis in vitro and in vivo. Endogenous miR-329 expression was downregulated by VEGF and tumor necrosis factor alpha (TNF-alpha), resulting in the elevation of CD146 in endothelial cells. Upregulation of CD146 facilitated an endothelial response to VEGF-induced SRC kinase family (SKF)/p38 mitogen-activated protein kinase (MAPK)/NF-kappaB activation and consequently promoted endothelial cell migration and tube formation. Our animal experiments showed that treatment with miR-329 repressed excessive CD146 expression on blood vessels and significantly attenuated neovascularization in a mouse model of pathological angiogenesis. Our findings provide the first evidence that CD146 expression in angiogenesis is regulated by miR-329 and suggest that miR-329 could present a potential therapeutic tool for the treatment of angiogenic diseases. |
